Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 522,696	$ 329,930	$ 1,064,088	$ 1,100,108
Cost of goods sold	208,096	83,006	400,202	309,320
Gross margin	314,600	246,924	663,886	790,788
General and administrative expense	2,616,991	762,603	7,425,305	2,708,274
Operations expense	707,414	723,939	2,445,238	1,390,434
Sales and marketing expense	434,955	621,465	1,674,200	1,726,087
Total operating loss	(3,444,760)	(1,861,083)	(10,880,857)	(5,034,007)
Gain on revaluation of cash advances to Helomics			1,222,244
Other income	15,084		65,293
Other expense	578,836		1,967,895
Loss on equity method investment		645,786	439,637	1,606,294
Gain on revaluation of equity method investment			6,164,260
Net loss	(4,008,512)	(2,506,869)	(5,836,592)	(6,640,301)
Deemed dividend on Series E Convertible Preferred Stock	125,801		146,199
Net loss attributable to common shareholders per common shares – basic and diluted	$ (4,134,313)	$ (2,506,869)	$ (5,982,791)	$ (6,640,301)
Loss per common share - basic and diluted (in dollars per share)	$ (1.31)	$ (1.89)	$ (2.32)	$ (5.45)
Weighted average shares used in computation - basic and diluted (in shares)	3,146,609	1,325,261	2,581,014	1,217,829